,A review on generation of real-world evidence

被引:0
作者
Shunmugavelu, Meenakshi Sundaram [1 ]
Panda, Jayanta Ku [2 ]
Sehgal, Ashish [3 ]
Makkar, Brij Mohan [4 ]
机构
[1] Trichy Diabet Specialty Ctr, Trichy 620018, Tamil Nadu, India
[2] SCB Med Coll Odisha, Cuttack, Odisha, India
[3] Diabet Med, New Delhi, India
[4] Cleveland Clin, Adv Certificate Courses Diabet, New Delhi, India
来源
CLINICAL DIABETOLOGY | 2021年 / 10卷 / 05期
关键词
real-world evidence; healthcare policies; real-world data; pragmatic trials; policy making; RANDOMIZED CONTROLLED-TRIALS; INSULIN DEGLUDEC; BASAL INSULIN; MULTICENTER; LIMITATIONS; POPULATION; THERAPY; SAFETY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Real-world evidence can generate credible evidence to inform treatment decisions. Real-world evidence is in developmental stage and is fast evolving yet there are many unexplained attributes of real-world evidence. Real-world evidence informs benefit-risk decisions and is increasingly being used to support regulatory decision making. Potential benefits of real-world data include determination of extended outcomes including long-term outcomes, opportunities to partner with patients in innovative ways, and reduction in time and cost to generate dependable evidence. Limitations of real-world evidence include uncertainty in the quality of datasets and lack methodologic rigor in real-world studies. Use of real-world evidence for healthcare practices and policies is limited. Ensuring completeness, homogeneity, and linkage of datasets can enhance utility for epidemiological investigations and improvement in health outcomes. Research should be strengthened for real-world studies and technical standards should be reinforced. Collaborations of stakeholders is key to formulation and adoption of guidance for real-world evidence. Real-world data cannot be a substitute to randomized clinical studies but can possibly augment the generated evidence.
引用
收藏
页码:412 / 419
页数:8
相关论文
共 46 条
[11]  
European Medicines Agency, 2017, EMACHMPICH4362212017
[12]   Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study [J].
Fadini, Gian Paolo ;
Giordano, Carla ;
Salvi, Laura ;
Nicolucci, Antonio .
DIABETES THERAPY, 2020, 11 (12) :2909-2920
[13]   Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management [J].
Fawzy, Ameenathul M. ;
Yang, Wang-Yang ;
Lip, Gregory Y. H. .
EXPERT OPINION ON DRUG SAFETY, 2019, 18 (03) :187-209
[14]   Pragmatic Trials [J].
Ford, Ian ;
Norrie, John .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (05) :454-463
[15]   Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice-EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study [J].
Gautier, Jean-Francois ;
Martinez, Luc ;
Penfornis, Alfred ;
Eschwege, Eveline ;
Charpentier, Guillaume ;
Huret, Benoit ;
Madani, Suliya ;
Gourdy, Pierre .
ADVANCES IN THERAPY, 2015, 32 (09) :838-853
[16]  
Gliklich RichardE., 2010, Registries for evaluating patient outcomes: a user's guide, DOI DOI 10.23970/AHRQEPCREGISTRIES4
[17]   Real-world evidence for coverage decisions: opportunities and challenges [J].
Hampson, Grace ;
Towse, Adrian ;
Dreitlein, William B. ;
Henshall, Chris ;
Pearson, Steven D. .
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (12) :1133-1143
[18]   Attitudes of patients and physicians to insulin therapy in Japan: an analysis of the Global Attitude of Patients and Physicians in Insulin Therapy study [J].
Harashima, Shin-ichi ;
Nishimura, Akiko ;
Inagaki, Nobuya .
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (01) :5-11
[19]   Series: Pragmatic trials and real world evidence: Paper 7. Safety, quality and monitoring [J].
Irving, Elaine ;
van den Bor, Rutger ;
Welsing, Paco ;
Walsh, Veronica ;
Alfonso-Cristancho, Rafael ;
Harvey, Catherine ;
Gaiman, Nadia ;
Grobbee, Diederick E. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2017, 91 :6-12
[20]   Multidimensional Evidence Generation and FDA Regulatory Decision Making Defining and Using "Real-World" Data [J].
Jarow, Jonathan P. ;
LaVange, Lisa ;
Woodcock, Janet .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (08) :703-704